FDA Grants Fast Track Designation to Quoin Pharmaceuticals’ QRX003 for Peeling Skin Syndrome

Key Facts

1The FDA granted Fast Track Designation to QRX003, making it the first-ever therapy for Peeling Skin Syndrome to receive this status.

2The company expects to initiate a Phase 2/3 study in the second half of 2026, enrolling up to 12 patients in the U.S. and Europe.

In a move reflecting the accelerating pace of biotech innovation for rare diseases, Quoin Pharmaceuticals announced that the FDA has granted Fast Track Designation to its drug candidate QRX003. This marks the first-ever therapy for Peeling Skin Syndrome to receive such status, aimed at expediting the development and review of treatments for serious conditions with unmet medical needs. The designation follows the clearance of an Investigational New Drug (IND) application in July 2026.

According to the company's plans, a Phase 2/3 clinical study is expected to initiate in the second half of 2026, enrolling up to 12 pediatric and adult patients across the U.S. and Europe. The Fast Track status allows for more frequent interactions with the FDA and potential eligibility for Priority Review or Accelerated Approval if specific criteria are met. This regulatory milestone aligns with the company's strategy to address a broad range of rare and orphan indications through its innovative pipeline.

Monitoring the stock performance, QNRX closed at $6.90 (close September 21, 2026), having traded within a daily range of $6.76 to $7.14. With no major upcoming pharmaceutical-related events in the economic calendar for the next few days, investors will likely focus on future updates regarding the clinical study initiation scheduled for 2026 as the primary catalyst for the instrument.